Marizyme, Inc. aksje

Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, and dental care and thrombosi, as well as MATLOC 1, a lab on chip digital device, which is under development for screening of individuals at risk for the development of chronic kidney disease. The company also engages in the development of MAR-FG-001, a fat grafting technology for fat grafting procedures. The company was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.